Floatz logo

Abciximab

Acute Disease

Centocor, Inc.monoclonal_antibodyPhase 3Dormant
CC
42/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
27/ 100
Competitive Position
95/ 100

Competitive context

6 Active assets in the Acute Disease cohort.

Asset / SponsorPhaseRating
Paliperidone Palmitate 3-Month Formulation
Janssen Cilag N.V./S.A.
Phase 4BB
Vosaroxin
Sunesis Pharmaceuticals
Phase 2B
Tenecteplase
ProMedica Health System
Phase 2/3B
Obinutuzumab
Molecular Partners AG
Phase 1/2CCC
MP0533
Molecular Partners AG
Phase 1/2CCC

View all 9 →

Same molecule, other indications

Abciximab is also rated in:

stroke disorderDormant
CC
Indicative ·
46 / 100
View asset →
brain ischemiaDormant
CC
Indicative ·
42 / 100
View asset →
sickle cell diseaseDormant
C
Indicative ·
38 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →